Cooper, C L <br/><br/>
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.  [electronic resource] 

 -  Journal of clinical immunology  Nov 2004 
 - 693-701 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0271-9142 
<br/><br/><label>Standard No.: </label>10.1007/s10875-004-6244-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Adolescent<br/>Adult<br/>Antibody Formation<br/>Double-Blind Method<br/>Female<br/>Hepatitis B Surface Antigens--administration & dosage<br/>Hepatitis B Vaccines--administration & dosage<br/>Humans<br/>Immunophenotyping<br/>Male<br/>Membrane Glycoproteins--agonists<br/>Oligodeoxyribonucleotides--administration & dosage<br/>Receptors, Cell Surface--agonists<br/>T-Lymphocytes--immunology<br/>T-Lymphocytes, Cytotoxic--immunology<br/>Toll-Like Receptor 9<br/>Toll-Like Receptors<br/>Vaccines, Synthetic--administration & dosage